Abiopharma

🔍 Kim Vyacheslav (Executive)

Company: Joint Stock Co Kaspi.kz (KSPI)

Report Date: 2026-09-10

Detailed Transactions and Holdings:

• Sold 0 shares of American Depositary Shares, no par value (Derivative)
  Date: 2026-09-10 | Code: S | equity_swap_involved: false | shares_owned_after: 36,936,811.00 | transaction_form_type: 4 | Footnotes: F1, F2, F1, F1, F1
• Sold 0 shares of American Depositary Shares, no par value (Derivative)
  Date: 2026-09-10 | Code: S | equity_swap_involved: false | shares_owned_after: 36,901,807.00 | transaction_form_type: 4 | Footnotes: F1, F3, F1, F1, F1
• Sold 0 shares of American Depositary Shares, no par value (Derivative)
  Date: 2026-09-11 | Code: S | equity_swap_involved: false | shares_owned_after: 36,876,370.00 | transaction_form_type: 4 | Footnotes: F1, F4, F1, F1, F1
• Sold 0 shares of American Depositary Shares, no par value (Derivative)
  Date: 2026-09-11 | Code: S | equity_swap_involved: false | shares_owned_after: 36,869,549.00 | transaction_form_type: 4 | Footnotes: F1, F5, F1, F1, F1
• Sold 0 shares of American Depositary Shares, no par value (Derivative)
  Date: 2026-09-11 | Code: S | equity_swap_involved: false | shares_owned_after: 36,863,854.00 | transaction_form_type: 4 | Footnotes: F1, F6, F1, F1, F1
• Sold 0 shares of American Depositary Shares, no par value (Derivative)
  Date: 2026-09-14 | Code: S | equity_swap_involved: false | shares_owned_after: 36,854,114.00 | transaction_form_type: 4 | Footnotes: F1, F7, F1, F1, F1
• Sold 0 shares of American Depositary Shares, no par value (Derivative)
  Date: 2026-09-14 | Code: S | equity_swap_involved: false | shares_owned_after: 36,836,385.00 | transaction_form_type: 4 | Footnotes: F1, F8, F1, F1, F1
• Sold 0 shares of American Depositary Shares, no par value (Derivative)
  Date: 2026-09-14 | Code: S | equity_swap_involved: false | shares_owned_after: 36,830,982.00 | transaction_form_type: 4 | Footnotes: F1, F9, F1, F1, F1

Footnotes:

• F1: Each American Depositary Share (ADS) represents one common share of the issuer.
• F2: The price reported in Column 8 is a weighted average price. These ADSs were sold in multiple transactions at prices ranging from $96.895 to $97.89, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the U.S. Securities and Exchange Commission ("SEC"), upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
• F3: The price reported in Column 8 is a weighted average price. These ADSs were sold in multiple transactions at prices ranging from $97.8975 to $98.7, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
• F4: The price reported in Column 8 is a weighted average price. These ADSs were sold in multiple transactions at prices ranging from $97.185 to $98.18, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
• F5: The price reported in Column 8 is a weighted average price. These ADSs were sold in multiple transactions at prices ranging from $98.19 to $99.17, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
• F6: The price reported in Column 8 is a weighted average price. These ADSs were sold in multiple transactions at prices ranging from $99.22 to $99.94, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
• F7: The price reported in Column 8 is a weighted average price. These ADSs were sold in multiple transactions at prices ranging from $98.51 to $99.50, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
• F8: The price reported in Column 8 is a weighted average price. These ADSs were sold in multiple transactions at prices ranging from $99.55 to $100.55, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
• F9: The price reported in Column 8 is a weighted average price. These ADSs were sold in multiple transactions at prices ranging from $100.555 to $100.875, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
• REMARKS: Due to the issuer's status as a foreign private issuer pursuant to Rule 3a12-3(b) under the Securities Exchange Act of 1934 (the "Act"), the reporting person's transactions in the issuer's equity securities are exempt from Sections 16(b) and 16(c) of the Act.